MedTrace Logo

Allergen Immunotherapy in Allergic Patients

NCT02040974 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 120

Last updated 2014-01-20

No results posted yet for this study

Summary

Our aim was to evaluate the effectiveness of subcutaneous allergen immunotherapy with the symptom scores (RSS), visual analog scale (VAS) and medication scores (MS) and the impact on quality of life with rhinoconjunctivitis quality of life questionnaire (RQLQ) in allergic rhinitis patients sensitized to different allergens. Also the development of new sensitizations and asthma during the immunotherapy were determined.

Conditions

  • Allergic Rhinitis

Sponsors & Collaborators

  • Istanbul University

    lead OTHER

Principal Investigators

  • Mustafa Demirturk · Istanbul Faculty of Medicine

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2014-01-31
Completion
2014-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02040974 on ClinicalTrials.gov